Affordable Access

Publisher Website

Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers

Authors
Journal
International Journal of Breast Cancer
2090-3170
Publisher
Hindawi Publishing Corporation
Publication Date
Volume
2011
Identifiers
DOI: 10.4061/2011/481563
Keywords
  • Clinical Study
Disciplines
  • Biology
  • Medicine

Abstract

Breast-conserving therapy (BCT) for sporadic breast cancer has been widely accepted by surgeons and patients alike. While BCT is associated with a higher risk of ipsilateral breast tumor recurrence (IBTR), it has not been shown to decrease overall survival (OS) in comparison with mastectomy. Many women with a BRCA1/2 mutation opt for mastectomy instead of breast-conserving measures at the time of a breast cancer diagnosis. In some cases, this is due to fear of aggressive disease, but to date, there have been no studies offering strong evidence that breast conservation should not be offered to these women. BRCA1/2-associated breast cancer has not been found to be more aggressive or resistant to treatment than comparable sporadic tumors, and no study has shown an actual survival advantage for mastectomy in appropriately treated affected mutation carriers. This paper reviews the available literature for breast conservation and surgical decision making in BRCA1/2 mutation carriers.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Prophylactic oophorectomy in BRCA1 and BRCA2 mutat...

on European Journal of Cancer November 2002

Prophylactic oophorectomy in BRCA1 and BRCA2 mutat...

on Journal of Clinical Oncology Nov 01, 2000

Prophylactic oophorectomy in carriers of BRCA1 or...

on New England Journal of Medicin... May 23, 2002
More articles like this..